| Mrs Julia Marie Ontiveros, NP | |
|
1806 Quincy St, Plainview, TX 79072-4206 | |
| (806) 288-7891 | |
| (806) 288-7920 |
| Full Name | Mrs Julia Marie Ontiveros |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 1806 Quincy St, Plainview, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326650821 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 1008919 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Covenant Hospital Plainview | Plainview, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Methodist Hospital Plainview Texas | 0749179521 | 14 |
News Archive
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Researchers report finding a new blood biomarker that enables close to 98 percent accuracy in predicting the spread of prostate cancer to regional lymph nodes.
Researchers from Boston University Schools of Medicine (BUSM) and Public Health along with Boston Medical Center have found children's academic achievement test scores not affected by intrauterine exposure to cocaine, tobacco or marijuana.
› Verified 2 days ago
| Entity Name | Methodist Hospital Plainview Texas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831220904 PECOS PAC ID: 0749179521 Enrollment ID: O20040727000792 |
News Archive
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Researchers report finding a new blood biomarker that enables close to 98 percent accuracy in predicting the spread of prostate cancer to regional lymph nodes.
Researchers from Boston University Schools of Medicine (BUSM) and Public Health along with Boston Medical Center have found children's academic achievement test scores not affected by intrauterine exposure to cocaine, tobacco or marijuana.
› Verified 2 days ago
| Entity Name | West Texas Family Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841628211 PECOS PAC ID: 3971734955 Enrollment ID: O20140320000538 |
News Archive
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Researchers report finding a new blood biomarker that enables close to 98 percent accuracy in predicting the spread of prostate cancer to regional lymph nodes.
Researchers from Boston University Schools of Medicine (BUSM) and Public Health along with Boston Medical Center have found children's academic achievement test scores not affected by intrauterine exposure to cocaine, tobacco or marijuana.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Julia Marie Ontiveros, NP 1806 Quincy St, Plainview, TX 79072-4206 Ph: (806) 288-7891 | Mrs Julia Marie Ontiveros, NP 1806 Quincy St, Plainview, TX 79072-4206 Ph: (806) 288-7891 |
News Archive
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Researchers report finding a new blood biomarker that enables close to 98 percent accuracy in predicting the spread of prostate cancer to regional lymph nodes.
Researchers from Boston University Schools of Medicine (BUSM) and Public Health along with Boston Medical Center have found children's academic achievement test scores not affected by intrauterine exposure to cocaine, tobacco or marijuana.
› Verified 2 days ago
Muming Chen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1806 Quincy St, Plainview, TX 79072 Phone: 806-288-7891 | |
Colby Rozean, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2222 W 24th St, Plainview, TX 79072 Phone: 806-291-5100 Fax: 806-291-3370 | |
Ruth Kristine Rector-wright, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 2606 Yonkers St # 1, Plainview, TX 79072 Phone: 806-296-7888 Fax: 806-296-7893 | |
Lauren Swartz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2222 W 24th St, Plainview, TX 79072 Phone: 806-291-5100 Fax: 806-296-6853 | |
Robin Suzanne Stanfield, Family Medicine Medicare: Medicare Enrolled Practice Location: 2222 W 24th St, Plainview, TX 79072 Phone: 806-296-5531 | |
Kelsey Elaine Richardson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1208 N I27, Plainview, TX 79072 Phone: 806-291-5112 |